CNTN trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CNTN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, Canton Strategic Holdings Inc (CNTN) has a Wall Street consensus price target of N/A, based on estimates from 1 covering analysts. The company has a market capitalization of $113M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Hold, with 0 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CNTN trades at a trailing P/E of -2.4x. Analysts expect EPS to grow -25.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HALOHalozyme Therapeutics, Inc. | $11.4B | $95.97 | $110.00 | +14.6% | Buy | 11.1x | 27 |
PRTAProthena Corporation plc | $432M | $8.26 | $30.00 | +263.2% | Buy | 69.6x | 28 |
ALDXAldeyra The | $42M | $0.69 | $9.67 | +1293.6% | Buy | — | 19 |
CLDXCelldex Therapeutics, Inc. | $1.9B | $28.04 | $66.80 | +138.2% | Buy | — | 20 |
IMVTImmunovant, Inc. | $6.9B | $33.21 | $40.00 | +20.4% | Buy | — | 23 |
MDGLMadrigal Pharmaceuticals, Inc. | $9.7B | $421.99 | $684.80 | +62.3% | Buy | — | 25 |
AKBAAkebia Therapeutics, Inc. | $107M | $0.40 | $1.00 | +149.8% | Buy | — | 12 |
CGEMCullinan Therapeutics, Inc. | $570M | $9.28 | $35.00 | +277.4% | Buy | — | 8 |
AGENAgenus Inc. | $259M | $6.21 | $25.00 | +302.6% | Buy | 23.2x | 12 |
INVAInnoviva, Inc. | $1.4B | $18.30 | $38.00 | +107.7% | Buy | 7.6x | 11 |
Quick answers to the most common questions about buying CNTN stock.
The consensus price target for CNTN is $N/A, close to the current price of $1.42 (N/A% implied move). Based on 1 analyst estimates, the stock appears fairly valued near current levels.
CNTN has a consensus rating of "Hold" based on 1 Wall Street analysts. The rating breakdown is mixed, with 1 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
CNTN's current price is $1.42 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for CNTN, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
CNTN is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CNTN stock forecast based on 1 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Hold".
CNTN appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CNTN analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.